Hetero Labs v. AbbVie: ORILISSA Elagolix Infringement Action Dismissed in 15 Days
Hetero Labs filed an infringement complaint against AbbVie in Delaware District Court targeting ORILISSA (elagolix sodium) tablets under U.S. Patent App. No. 18/168221, then voluntarily dismissed without prejudice just 15 days later — before AbbVie filed any response.
A 15-Day ORILISSA Patent Filing That Raises More Questions Than Answers
On April 7, 2025, Hetero Labs, Ltd. filed an infringement action against AbbVie, Inc. in the U.S. District Court for the District of Delaware, asserting U.S. Patent No. 12,102,637 B2 (Application No. 18/168221) in connection with AbbVie’s branded ORILISSA product — elagolix sodium tablets in 150 mg and 200 mg base equivalent strengths. ORILISSA is an FDA-approved GnRH receptor antagonist indicated for endometriosis-associated pain and, in combination formulation, for uterine fibroids.
Just 15 days after filing, on April 22, 2025, Hetero voluntarily dismissed its own complaint pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i) — without prejudice. This procedural mechanism is available as of right before the defendant serves an answer or a motion for summary judgment, and the public docket reflects no response from AbbVie prior to dismissal. No costs or fee-shifting ruling was entered.
The speed of the dismissal — 15 days, before the defendant even appeared — suggests the filing may have been a tactical or procedural placeholder, potentially linked to ANDA patent certification timelines, licensing discussions, or a strategic reassessment of claim scope. The without-prejudice designation preserves Hetero’s right to refile, leaving the underlying dispute unresolved. What drove the near-immediate withdrawal remains undisclosed on the public record.
Filing to Voluntary dismissal in 15 days
Case resolved in 15 days — well below the median ANDA litigation timeline of 2–3 years
Voluntarily dismissed: what Rule 41 without prejudice means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s right to dismiss before defendant responds
Federal Rule of Civil Procedure 41(a)(1)(A)(i) permits a plaintiff to dismiss its complaint as of right — without court approval — before the opposing party serves an answer or a motion for summary judgment. Here, AbbVie had not yet responded, so Hetero exercised this right unilaterally. The dismissal is self-executing upon filing. No judicial order was required, and no merits analysis occurred.
Pre-answer voluntary dismissalThe public record does not specify final settlement terms
A dismissal without prejudice means Hetero retains the right to refile the same claims against AbbVie in the future. This is legally distinct from a dismissal with prejudice, which would bar refiling permanently. Hetero’s filing explicitly states ‘without prejudice,’ so no res judicata effect attaches. However, the public record is silent on whether any side agreement, licensing term, or commercial arrangement accompanied the dismissal.
Right to refile preservedHetero exits without a merits ruling — and keeps its options open
By dismissing without prejudice, Hetero avoids any adverse finding on validity, infringement, or claim scope. The ‘637 patent remains intact and enforceable. Hetero can refile if circumstances change — for example, if ANDA approval progresses, licensing talks stall, or a claim amendment strengthens its position. The 15-day window suggests the decision to withdraw was made quickly after filing, consistent with a resolved negotiating point or a tactical pivot.
No adverse merits findingAbbVie faces no injunction — but the threat is not extinguished
AbbVie never had to answer the complaint, avoiding early litigation cost and any risk of adverse claim construction. However, with the dismissal carrying no prejudice, AbbVie cannot treat this as a resolved matter. Hetero retains the right to reassert the ‘637 patent, and the ORILISSA franchise — a multi-hundred-million-dollar product — remains a continued target for generic entry challenges. AbbVie’s IP enforcement posture around elagolix warrants ongoing monitoring.
Threat not extinguishedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Hetero Labs, Ltd. | Company | Generic pharmaceutical manufacturer — holder of US12102637B2 covering elagolix sodium formulationsSearch in Eureka ↗ |
| Defendant | AbbVie, Inc. | Company | AbbVie, Inc. — originator and brand holder of ORILISSA (elagolix sodium) for endometriosis and uterine fibroidsSearch in Eureka ↗ |
| Plaintiff counsel | Andrew John Koopman | Attorney | Counsel for Hetero Labs, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Geoffrey Graham Grivner | Attorney | Counsel for Hetero Labs, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Kody Macgyver Sparks | Attorney | Counsel for Hetero Labs, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Buchanan, Ingersoll & Rooney PC | Law Firm | Representing Hetero Labs, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) explicitly and designates the withdrawal as without prejudice — precise language that carries specific legal consequences. Because no answer or dispositive motion had been filed by AbbVie, Hetero exercised an absolute right requiring no judicial approval. The phrasing forecloses any argument of res judicata, preserving Hetero’s ability to reassert the ‘637 patent. No merits, validity, or infringement findings attach to this termination.
US12102637B2 — elagolix sodium tablet formulation for endometriosis and uterine fibroids
U.S. Patent No. 12,102,637 B2 (Application No. 18/168,221) covers formulations of elagolix sodium — a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist. The patent is directed to pharmaceutical compositions of elagolix sodium in tablet form, including the 150 mg and 200 mg base equivalent dosage strengths marketed by AbbVie under the brand ORILISSA. Elagolix acts by competitively blocking pituitary GnRH receptors, suppressing estrogen production — a mechanism central to managing endometriosis-associated pain.
For the pharmaceutical sector, formulation patents on small-molecule GnRH antagonists like elagolix carry significant commercial weight. ORILISSA generates substantial annual revenues for AbbVie, and any successful generic entry would erode that franchise rapidly. The ‘637 patent, if valid and infringed, could support injunctive relief blocking Hetero’s ANDA-based launch. The absence of a merits ruling in this case leaves claim scope unadjudicated — a material uncertainty for any competitor or investor modelling generic entry timelines for elagolix sodium products.
Should you run an FTO analysis against US12102637B2?
Any company developing, manufacturing, or seeking regulatory approval for elagolix sodium tablet formulations — including ANDA filers, contract manufacturers, and 505(b)(2) applicants — should conduct a freedom-to-operate analysis against US12102637B2. The patent remains in force, no court has narrowed its claims through litigation, and the without-prejudice dismissal means enforcement risk has not been extinguished. R&D teams working on GnRH antagonist oral dosage forms should also assess whether continuation or divisional patents in the same family present additional exposure.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US12102637B2, identify prosecution history estoppel, and surface related family members that could affect your product design. For pharmaceutical teams tracking ORILISSA generic entry, Eureka can also monitor new AbbVie patent filings in the elagolix space and alert you to docket activity in Delaware — giving your legal and commercial teams advance notice before a 30-month stay clock starts ticking.
Run a freedom-to-operate analysis on US12102637B2 to assess your product’s exposure
Run FTO in Eureka →Similar elagolix and GnRH antagonist patent cases in Delaware District Court
Explore related Hatch-Waxman and pharmaceutical patent infringement cases involving elagolix sodium and GnRH antagonist formulations filed in Delaware District Court.
What this case signals for the elagolix and GnRH antagonist IP landscape
A 15-day filing-and-withdrawal cycle in Delaware rarely reflects a simple change of mind — it typically signals a shifting negotiating dynamic.
Without-prejudice dismissals in ANDA litigation often precede refiling or settlement
In Hatch-Waxman-adjacent disputes, early voluntary dismissals without prejudice frequently coincide with licensing negotiations, consent judgment drafting, or strategic repositioning ahead of FDA approval milestones. Hetero’s rapid withdrawal is consistent with this pattern, though no public disclosure confirms any agreement.
The ‘637 patent’s survival means ORILISSA’s IP moat is still being tested
US12102637B2 remains in force. Any company developing or commercialising elagolix sodium formulations — including other ANDA filers — should treat this patent as an active enforcement risk. The lack of a merits ruling means claim scope has not been adjudicated, leaving uncertainty for freedom-to-operate analyses across the elagolix product class.
Hetero v AbbVie — key questions answered
Hetero Labs filed an infringement complaint against AbbVie in Delaware District Court on April 7, 2025, asserting US12102637B2 against ORILISSA elagolix sodium tablets. On April 22, 2025 — just 15 days later — Hetero voluntarily dismissed the complaint without prejudice under Rule 41(a)(1)(A)(i), before AbbVie filed any response. The public record does not disclose what prompted the rapid withdrawal.
A without-prejudice dismissal means Hetero retains the right to refile the same patent infringement claims against AbbVie in the future. No res judicata or claim preclusion effect attaches. The ‘637 patent is unaffected and remains enforceable. This is legally distinct from a dismissal with prejudice, which would permanently bar Hetero from bringing the same claims again.
US12102637B2 (Application No. 18/168,221) covers pharmaceutical formulations of elagolix sodium in oral tablet form. Elagolix is a non-peptide GnRH receptor antagonist that suppresses estrogen production and is indicated for endometriosis-associated pain and uterine fibroids. AbbVie markets elagolix sodium as ORILISSA in 150 mg and 200 mg base equivalent tablet strengths.
No merits ruling was issued. The case was voluntarily dismissed by Hetero Labs before AbbVie filed any response, so no finding of infringement, validity, or non-infringement was made. AbbVie did not obtain a judgment in its favour — the case simply ended procedurally at Hetero’s initiative. The patent dispute over elagolix sodium remains unresolved on the merits.
Yes. The dismissal was explicitly entered without prejudice under Rule 41(a)(1)(A)(i), preserving Hetero’s right to refile. However, if Hetero files a second action asserting the same claims, a subsequent voluntary dismissal would typically operate as an adjudication on the merits under Rule 41(a)(1)(B)’s ‘two-dismissal rule,’ making strategic timing of any refile important.
PatSnap Eureka searches patents and litigation data to answer instantly.